Cantor Fitzgerald cut shares of Alcobra Ltd. (NASDAQ:ADHD) from a buy rating to a hold rating in a research report released on Thursday. Cantor Fitzgerald currently has $2.00 price objective on the stock.
ADHD has been the topic of a number of other reports. WBB Securities downgraded shares of Alcobra from a hold rating to a sell rating and reduced their target price for the stock from $5.00 to $4.00 in a research report on Monday, September 12th. Jefferies Group reaffirmed a buy rating on shares of Alcobra in a research report on Thursday, August 25th. Goldman Sachs Group Inc. reaffirmed a buy rating on shares of Alcobra in a research report on Thursday, September 1st. Piper Jaffray Cos. reaffirmed an overweight rating and issued a $10.00 target price on shares of Alcobra in a research report on Tuesday, August 30th. Finally, Barclays PLC started coverage on shares of Alcobra in a research report on Monday, August 1st. They issued an equal weight rating and a $8.00 target price on the stock. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the stock. The company has an average rating of Hold and an average target price of $6.47.
Shares of Alcobra (NASDAQ:ADHD) opened at 2.60 on Thursday. Alcobra has a 12-month low of $1.95 and a 12-month high of $8.78. The company’s 50-day moving average is $4.62 and its 200-day moving average is $4.50. The stock’s market cap is $71.66 million.
Alcobra (NASDAQ:ADHD) last released its earnings results on Tuesday, August 30th. The company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.01. On average, equities research analysts anticipate that Alcobra will post ($0.94) earnings per share for the current year.
A number of institutional investors have recently bought and sold shares of the stock. Stifel Financial Corp boosted its position in Alcobra by 34.2% in the second quarter. Stifel Financial Corp now owns 62,000 shares of the company’s stock valued at $278,000 after buying an additional 15,800 shares in the last quarter. Jefferies Group LLC bought a new position in Alcobra during the second quarter valued at about $533,000. Palo Alto Investors LLC boosted its position in Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock valued at $1,225,000 after buying an additional 18,600 shares in the last quarter. BlackRock Fund Advisors boosted its position in Alcobra by 11.4% in the first quarter. BlackRock Fund Advisors now owns 354,614 shares of the company’s stock valued at $1,344,000 after buying an additional 36,218 shares in the last quarter. Finally, VHCP Management LLC boosted its position in Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock valued at $2,799,000 after buying an additional 138,813 shares in the last quarter. Institutional investors and hedge funds own 73.69% of the company’s stock.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.